FUMARYL DIKETOPIPERAZINE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C20H28N4O8
Molecular Weight	452.4583
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	2
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)\C=C\C(=O)NCCCC[C@@H]1NC(=O)[C@H](CCCCNC(=O)\C=C\C(O)=O)NC1=O

InChI

InChIKey=BBNKIRVUCQNAQR-FETIZUMASA-N

InChI=1S/C20H28N4O8/c25-15(7-9-17(27)28)21-11-3-1-5-13-19(31)24-14(20(32)23-13)6-2-4-12-22-16(26)8-10-18(29)30/h7-10,13-14H,1-6,11-12H2,(H,21,25)(H,22,26)(H,23,32)(H,24,31)(H,27,28)(H,29,30)/b9-7+,10-8+/t13-,14-/m0/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20920436 | https://www.ncbi.nlm.nih.gov/pubmed/26150567

Fumaryl diketopiperazine, a pharmaceutical excipient is used as a part of Technosphere inhalation system. This system delivered drugs to the deep lung and have been used to administer insulin and glucagon-like peptide-1 via inhalation in clinical studies. Afrezza that is formulated with an excipient, fumaryl diketopiperazine represents a novel ultrarapid-acting insulin formulation indicated for use in improving glycemic control in selected patients with type 1 or type 2 diabetes mellitus.

Approval Year

PubMed

Title	Date	PubMed
A delineation of diketopiperazine self-assembly processes: understanding the molecular events involved in Nepsilon-(fumaroyl)diketopiperazine of L-Lys (FDKP) interactions.	2008 Mar-Apr	18254597
Pharmacokinetic characterization of the novel pulmonary delivery excipient fumaryl diketopiperazine.	2010 Sep 1	20920436

Name

Type

Language

FUMARYL DIKETOPIPERAZINE

Common Name

English

2-BUTENOIC ACID, 4,4'-(((2S,5S)-3,6-DIOXO-2,5-PIPERAZINEDIYL)BIS(4,1-BUTANEDIYLIMINO))BIS(4-OXO-, (2E,2'E)-

Common Name

English

2-BUTENOIC ACID, 4,4'-((3,6-DIOXO-2,5-PIPERAZINEDIYL)BIS(4,1-BUTANEDIYLIMINO))BIS(4-OXO-, (2S-(2.ALPHA.(E),5.ALPHA.(E)))-

Common Name

English

FDKP

Common Name

English

Code System Code Type Description

CAS

176738-91-3